FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
AstraZeneca just showed how fast an established cancer drug can achieve a crucial line extension.
Just two months after the pharma giant and its partners …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
